Format

Send to

Choose Destination
Nat Commun. 2017 Aug 30;8(1):386. doi: 10.1038/s41467-017-00540-5.

ATRX is a regulator of therapy induced senescence in human cells.

Author information

1
The Louis V. Gerstner Graduate School of Biomedical Sciences, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, 10065, USA.
2
Program in Molecular Biology, Memorial Sloan Kettering Cancer Center, New York, 10065, USA.
3
The New York Genome Center, New York, 10013, USA.
4
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, 10065, USA.
5
Department of Medicine, Weill College of Medicine, Cornell University, New York, 10065, USA.
6
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, 10065, USA.
7
The Louis V. Gerstner Graduate School of Biomedical Sciences, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, 10065, USA. koffa@mskcc.org.
8
Program in Molecular Biology, Memorial Sloan Kettering Cancer Center, New York, 10065, USA. koffa@mskcc.org.

Abstract

Senescence is a state of stable cell cycle exit with important implications for development and disease. Here, we demonstrate that the chromatin remodeling enzyme ATRX is required for therapy-induced senescence. ATRX accumulates in nuclear foci and is required for therapy-induced senescence in multiple types of transformed cells exposed to either DNA damaging agents or CDK4 inhibitors. Mobilization into foci depends on the ability of ATRX to interact with H3K9me3 histone and HP1. Foci form soon after cells exit the cell cycle, before other hallmarks of senescence appear. Eliminating ATRX in senescent cells destabilizes the senescence-associated heterochromatic foci. Additionally, ATRX binds to and suppresses expression from the HRAS locus; repression of HRAS is sufficient to promote the transition of quiescent cells into senescence and preventing repression blocks progression into senescence. Thus ATRX is a critical regulator of therapy-induced senescence and acts in multiple ways to drive cells into this state.Therapy induced senescence (TIS) is a growth suppressive program activated by cytostatic agents in some cancer cells. Here the authors show that the chromatin remodeling enzyme ATRX is a regulator of TIS and drives cells into this state via multiple mechanisms.

PMID:
28855512
PMCID:
PMC5577318
DOI:
10.1038/s41467-017-00540-5
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center